A Randomized, Double-Blind, Placebo-Controlled, Multicentered Study to Evaluate the Efficacy and Safety of MEI005 in Reducing Submental Fat in Chinese Adults
Aesthetic Surgery Journal · 2025
DOI: 10.1093/asj/sjaf031 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Aesthetic Surgery Journal, 2025. Verfasst von Wenyun Ting und 18 weiteren Autor:innen. Hauptthemen laut MEDLINE: Deoxycholic Acid, Subcutaneous Fat, Cosmetic Techniques. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Submental fat (SMF) is a common aesthetic concern traditionally treated with liposuction. Nonsurgical alternatives, like injectable deoxycholic acid, are gaining popularity. However, no related products have been clinically approved in China.
Objectives
This study evaluated the efficacy and safety of MEI005, a deoxycholic acid–based injectable formulation, in reducing SMF in Chinese adults.
Methods
This multicenter, randomized, double-blind, placebo-controlled Phase III trial included 325 Chinese adults with moderate-to-severe SMF. Participants received MEI005 or a placebo injection every 28 days for up to 6 sessions. Primary endpoints were ≥2-grade improvements in Clinician and Patient-Reported Submental Fat Rating Scales (CR-SMFRS and PR-SMFRS). Secondary endpoints included SMF volume reductions measured by MRI; patient-reported outcomes on the Patient-Reported Submental Fat Impact Scale (PR-SMFIS) and Subject Self-Rating Scale (SSRS); and SMF thickness reductions measured by caliper. Adverse events (AEs), self-reports, clinical examinations, and checks for skin laxity were monitored.
Results
At 12 weeks posttreatment, 18.9% of MEI005 recipients demonstrated simultaneously ≥2-grade CR-SMFRS and PR-SMFRS improvement vs 1.8% for placebo (P < .001). Additionally, 68.9% of MEI005 group participants achieved simultaneously ≥1-grade improvement in CR-SMFRS and PR-SMFRS, compared with 21.6% of placebo (P < .001). MRI revealed ≥10% SMF volume reduction in 50% of MEI005 patients vs 15.2% of placebo (P < .001). Scores on the PR-SMFIS and SSRSs showed greater psychological improvement and satisfaction among MEI005 recipients. Vernier caliper measurements showed a 21.42% thickness reduction vs 6.32% (P < .001). AEs were mostly mild to moderate.
Conclusions
MEI005 effectively reduces SMF, offering a safe, minimally invasive option for Chinese adults. Level of Evidence: 2
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Hongwei Liu, Nanze Yu
Zitieren
APA
Ting, W., Wen, J., Li, Z., Sun, J., Zhang, J., Shu, M., Liu, H., He, L., Yu, B., Jiang, N., Xue, C., Tan, Q., Xu, X., Wu, S., Jian, D., Zhao, H., Wang, L., Yu, N., & Wang, X. (2025). A Randomized, Double-Blind, Placebo-Controlled, Multicentered Study to Evaluate the Efficacy and Safety of MEI005 in Reducing Submental Fat in Chinese Adults. Aesthetic Surgery Journal. https://doi.org/10.1093/asj/sjaf031
Vancouver
Ting W, Wen J, Li Z, Sun J, Zhang J, Shu M, et al. A Randomized, Double-Blind, Placebo-Controlled, Multicentered Study to Evaluate the Efficacy and Safety of MEI005 in Reducing Submental Fat in Chinese Adults. Aesthetic Surgery Journal. 2025. doi:10.1093/asj/sjaf031
BibTeX
@article{Ting2025,
author = {Ting, Wenyun and Wen, Junxian and Li, Zhijin and Sun, Jiaming and Zhang, Jiaping and Shu, Maoguo and Liu, Hongwei and He, Li and Yu, Bo and Jiang, Nan and Xue, Chunyu and Tan, Qian and Xu, Xuewen and Wu, Sufan and Jian, Dan and Zhao, Hongyi and Wang, Lei and Yu, Nanze and Wang, Xiaojun},
title = {A Randomized, Double-Blind, Placebo-Controlled, Multicentered Study to Evaluate the Efficacy and Safety of MEI005 in Reducing Submental Fat in Chinese Adults},
journal = {Aesthetic Surgery Journal},
year = {2025},
doi = {10.1093/asj/sjaf031}
}
EUVIMED